INVESTORS & MEDIA
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
- Fourth quarter 2022 revenues decreased 31% to
$3.41 billionversus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14%
- Full year 2022 revenues decreased 24% to
$12.17 billionversus full year 2021; excluding REGEN-COV and Ronapreve(a)(b), revenues increased 17%
- Fourth quarter 2022 EYLEA®
U.S.net sales decreased 3% to $1.50 billionversus fourth quarter 2021; full year 2022 EYLEA U.S.net sales increased 8% to $6.26 billionversus 2021
- Fourth quarter 2022 Dupixent® global net sales (recorded by Sanofi) increased 38% to
$2.45 billionversus fourth quarter 2021; full year 2022 Dupixent global net sales increased 40% to $8.68 billionversus 2021
- Fourth quarter 2022 GAAP diluted EPS of
$10.50and non-GAAP diluted EPS(a) of $12.56; includes unfavorable $0.21impact from acquired IPR&D charge
- Aflibercept 8 mg BLA for neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) submitted to FDA in
- FDA approved Libtayo® in combination with chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC)
European Commissionapproved Dupixent for adults with prurigo nodularis and adults and adolescents with eosinophilic esophagitis (EoE)
$3.4 billionto business development and share repurchases in 2022; new $3.0 billionshare repurchase program authorized in January 2023
"In 2022, Regeneron reported record revenue for EYLEA, Dupixent and Libtayo and made exciting progress across the entire pipeline," said
|Three Months Ended
|($ in millions, except per share data)||2022||2021||% Change||2022||2021||% Change|
|Total revenues excluding
|GAAP net income||$||1,197||$||2,229||(46%)||$||4,338||$||8,075||(46%)|
|GAAP net income per share - diluted||$||10.50||$||19.69||(47%)||$||38.22||$||71.97||(47%)|
|Non-GAAP net income(a)||$||1,449||$||2,677||(46%)||$||5,164||$||8,454||(39%)|
|Non-GAAP net income per share - diluted(a)||$||12.56||$||23.42||(46%)||$||44.98||$||74.35||(40%)|
"We were pleased with our fourth-quarter and full-year 2022 financial performance, highlighted by revenue growth of 14% and 17%, respectively, when excluding contributions from
Key Pipeline Progress
Regeneron has approximately 35 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications. Updates from the clinical pipeline include:
Aflibercept 8 mg
- A Biologics License Application (BLA) for the treatment of wet AMD and DME was submitted to the
U.S. Food and Drug Administration(FDA) in December 2022. The Company is utilizing a priority review voucher in connection with the submission.
EYLEA (aflibercept) Injection
December 2022, the European Commission(EC) approved EYLEA for the treatment of retinopathy of prematurity (ROP) in preterm infants. The supplemental BLA (sBLA) for EYLEA to treat ROP in preterm infants is currently under review by the FDA, with a target action date of February 11, 2023.
December 2022, the EC approved Dupixent for the treatment of adult patients with moderate-to-severe prurigo nodularis who are candidates for systemic therapy, making Dupixent the first and only targeted medicine specifically indicated to treat prurigo nodularis in Europe.
January 2023, the EC also approved Dupixent for the treatment of adults and adolescents with EoE, making Dupixent the first and only targeted medicine specifically indicated to treat EoE in Europe.
European Medicines Agency's(EMA) Committee for Medicinal Productsfor Human Use (CHMP) adopted a positive opinion for Dupixent to treat children aged 6 months to 5 years with severe atopic dermatitis. The ECdecision is expected in the coming months.
- An sBLA for the treatment of adult and adolescent patients with chronic spontaneous urticaria (CSU) was submitted.
November 2022, the FDA approved Libtayo in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC.
November 2022, the EC approved Libtayo as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. In December 2022, the Ministry of Health, Labour and Welfare(MHLW) in Japanalso approved Libtayo in advanced or recurrent cervical cancer.
Fianlimab, an antibody to LAG-3
- A Phase 3 study in first-line adjuvant melanoma was initiated.
Linvoseltamab, a bispecific antibody targeting BCMA and CD3
- The Company announced positive initial data from a pivotal Phase 2 expansion cohort evaluating linvoseltamab at the 200 mg dose in patients with heavily pre-treated, relapsed/refractory multiple myeloma. The results were presented at the
American Society of Hematology(ASH) Annual Meeting and Exposition.
Odronextamab, a bispecific antibody targeting CD20 and CD3
- Positive data were also presented at ASH from two cohorts of a pivotal Phase 2 trial studying odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
- A BLA for pozelimab, an antibody to C5, for the treatment of CD55-deficient protein-losing enteropathy (CHAPLE) was submitted.
- The FDA accepted for priority review the sBLA for Kevzara® (sarilumab) to treat polymyalgia rheumatica (PMR), with a target action date of
February 28, 2023.
- The FDA accepted for priority review the sBLA for Evkeeza® (evinacumab) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH), with a target action date of
March 30, 2023.
Corporate and Business Development Updates
November 2022, the Company and CytomX Therapeutics, Inc. entered into a license and collaboration agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform. Under the terms of the agreement, the Company made an upfront payment of $30 millionand will be responsible for funding development and commercial activities, and CytomX will be eligible to receive future target nomination payments and preclinical, clinical, and commercial milestone payments as well as royalties on global net sales.
- The Company was included on the Dow Jones Sustainability World Index (
DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index ( DJSI North America) for the third year.
Select 2023 Milestones
|Aflibercept 8 mg||-||FDA decision on BLA for wet AMD and DME (third quarter 2023)|
|-||Report two-year data from PULSAR (wet AMD) and PHOTON (DME) Phase 3 studies (third quarter 2023)|
|EYLEA (aflibercept)||-||FDA decision on sBLA for ROP (target action date of
|Dupixent (dupilumab)||-||EC decision on regulatory submission for atopic dermatitis in pediatrics (6 months–5 years of age) (first half 2023)|
|-||Submit sBLA for EoE in pediatrics (mid-2023)|
|-||FDA decision on sBLA for CSU in adults and adolescents (second half 2023)|
|-||Report results from first Phase 3 study in COPD and Phase 3 study in chronic inducible urticaria - cold (first half 2023)|
|Solid Organ Oncology||-||Initiate Phase 3 study for fianlimab (in combination with Libtayo) in perioperative melanoma (mid-2023)|
|-||Initiate Phase 2/3 studies for fianlimab (in combination with Libtayo) in first-line advanced NSCLC (first half 2023) and Phase 2 study in perioperative NSCLC (second half 2023)|
|-||Report additional results from Phase 1/2 study of REGN5678 (PSMA and CD28 bispecific antibody) in combination with Libtayo in prostate cancer (2023)|
|-||Report initial data across solid organ oncology, including for CD3 bispecifics and CD28 costimulatory bispecifics (2023)|
|-||EC decision on regulatory submission for Libtayo (in combination with chemotherapy) in advanced NSCLC (first half 2023)|
|Odronextamab (CD20 and CD3 Bispecific Antibody)||-||Initiate Phase 3 studies in FL and DLBCL, including earlier lines of therapy (first half 2023)|
|-||Submit BLA for relapsed/refractory FL and DLBCL (second half 2023)|
|Linvoseltamab (BCMA and CD3 Bispecific Antibody)||-||Initiate Phase 3 study in multiple myeloma, including earlier lines of therapy (first half 2023)|
|-||Submit BLA for relapsed/refractory multiple myeloma (second half 2023)|
|Pozelimab (C5 Antibody)||-||FDA decision on BLA for CHAPLE (second half 2023)|
Fourth Quarter 2022 Financial Results
|($ in millions)||Q4 2022||Q4 2021||% Change||FY 2022||FY 2021||% Change|
|Net product sales:|
|Libtayo - ROW**||42||—||*||73||—||*|
|Total net product sales||1,699||3,975||(57%||)||6,894||12,117||(43%||)|
|Total revenues excluding
|* Percentage not meaningful.|
|** Rest of world (ROW). Effective
Net product sales of EYLEA in the
There were no sales of
Sanofi collaboration revenue increased 61% to $836 million in the fourth quarter of 2022, compared to the fourth quarter of 2021, and increased 50% to
Sanofi and Bayer collaboration revenue (and specifically, the share of profits the Company earned in connection with commercialization of products) was adversely impacted in 2022 by the
The Company recorded Roche collaboration revenue during full year 2022 and 2021 in connection with payments from Roche attributable to global gross profits from sales of Ronapreve. Roche collaboration revenue increased in the fourth quarter of 2022, compared to the fourth quarter of 2021, as no Roche collaboration revenue was recorded during the fourth quarter of 2021 since the Company owed a payment to Roche (which was recorded to Cost of goods sold) in connection with global gross profits of
Refer to Table 4 for a summary of collaboration revenue.
|($ in millions)||Q4 2022||Q4 2021||Q4 2022||Q4 2021|
|Research and development (R&D)**||$||1,043||$||738||41%||$||911||$||635||43%|
|Acquired in-process research and development (IPR&D)**||$||30||$||48||(38%||)||*||*||n/a|
|Selling, general, and administrative (SG&A)||$||661||$||560||18%||$||579||$||495||17%|
|Cost of goods sold (COGS)||$||302||$||812||(63%||)||$||126||$||559||(77%||)|
|Cost of collaboration and contract manufacturing (COCM)||$||238||$||171||39%||*||*||n/a|
|Other operating (income) expense, net||$||(7||)||$||(16||)||(56%||)||*||*||n/a|
|FY 2022||FY 2021||FY 2022||FY 2021|
|Research and development**||$||3,593||$||2,860||26%||$||3,169||$||2,544||25%|
|Acquired in-process research and development**||$||255||$||48||431%||*||*||n/a|
|Selling, general, and administrative||$||2,116||$||1,825||16%||$||1,853||$||1,606||15%|
|Cost of goods sold||$||800||$||1,773||(55%||)||$||507||$||1,470||(66%||)|
|Cost of collaboration and contract manufacturing||$||760||$||664||14%||*||*||n/a|
|Other operating (income) expense, net||$||(90||)||$||(46||)||96%||*||*||n/a|
|* GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been recorded.|
|** Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. See note (f) below for additional information.|
- GAAP and non-GAAP R&D expenses increased in the fourth quarter and full year of 2022, compared to the same periods in the prior year, driven by the impact of the 2022 amendments to the Sanofi collaboration agreements, additional costs incurred in connection with the Company's late-stage pipeline, an increase in clinical manufacturing activities, and higher headcount and headcount-related costs. The increase for the full year of 2022, compared to full year 2021, was partly offset by lower costs incurred in connection with development activities for
REGEN-COV and fasinumab.
- Acquired IPR&D for full year 2022 included a $195 million charge related to the Company's acquisition of
Checkmate Pharmaceuticals, Inc., a $30 million up-front payment in connection with the Company's collaboration agreement with CytomX (fourth quarter 2022), and a $20 million opt-in payment in connection with a product candidate under the Company's collaboration agreement with Adicet Bio, Inc. Acquired IPR&D for the fourth quarter and full year of 2021 included $34 million in aggregate up-front payments in connection with the Company's collaboration agreement with Nykode Therapeutics.
- GAAP and non-GAAP SG&A expenses increased in the fourth quarter and full year of 2022, compared to the same periods in the prior year, primarily due to an increase in commercialization-related expenses for Libtayo (as effective
July 1, 2022, the Company became solely responsible for the commercialization of Libtayo worldwide), higher contributions to an independent not-for-profit patient assistance organization, and higher headcount and headcount-related costs, partly offset by educational campaigns related to COVID-19 that did not recur during 2022.
- GAAP and non-GAAP COGS decreased in the fourth quarter and full year of 2022, compared to the same periods in the prior year, primarily due to the Company recognizing
U.S. REGEN-COV net product sales (and corresponding cost of goods sold) during 2021 and a 2021 payment of $260 millionowed by the Company in connection with global gross profits under its Roche collaboration agreement; such transactions did not recur in 2022. GAAP and non-GAAP COGS also decreased in 2022 since effective July 1, 2022, following the acquisition of Libtayo worldwide rights, the Company is no longer obligated to pay Sanofi for their share of U.S.Libtayo gross profits.
GAAP COGS also decreased in the fourth quarter and full year of 2022 due to lower inventory write-offs and reserves. Non-GAAP COGS excluded certain charges related to
REGEN-COV (primarily inventory write-offs and reserves) of $134 millionand $197 millionin the fourth quarter and full year of 2022, respectively, and $232 millionin each of the fourth quarter and full year of 2021.
- Other operating (income) expense, net, for full year 2022 included the recognition of $44 million (an increase to other operating income) as a result of discontinuing further clinical development of fasinumab related to the Company's Teva and
Mitsubishi Tanabe Pharmacollaborative arrangements.
Other Financial Information
GAAP other income (expense) included the recognition of net unrealized gains on equity securities of $81 million in the fourth quarter of 2022, compared to
In the fourth quarter and full year 2022, the Company's GAAP effective tax rate (ETR) was 9.6% and 10.7%, respectively, compared to 11.0% and 13.4% in the fourth quarter and full year 2021, respectively. The GAAP ETR in the fourth quarter and full year 2022, compared to the same periods in the prior year, included a higher benefit from the proportion of income earned in foreign jurisdictions with tax rates lower than the
GAAP net income per diluted share was
During the full year 2022, the Company repurchased shares of common stock under its share repurchase program, and recorded the cost of the shares, or
2023 Financial Guidance(c)
The Company's full year 2023 financial guidance consists of the following components:
|GAAP gross margin on net product sales(d)||88%–90%|
|Non-GAAP gross margin on net product sales(a)(d)||90%–92%|
|Capital expenditures*||$825–$950 million|
|GAAP effective tax rate||10%–12%|
|Non-GAAP effective tax rate(a)||11%–13%|
|* GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been or are expected to be recorded.|
A reconciliation of full year 2023 GAAP to non-GAAP financial guidance is included below:
|($ in millions)||Low||High|
|Stock-based compensation expense||470||500|
|Acquisition-related integration costs||5||10|
|Stock-based compensation expense||310||330|
|Acquisition-related integration costs||20||40|
|GAAP gross margin on net product sales||88%||90%|
|Stock-based compensation expense||1%||1%|
|Intangible asset amortization expense||1%||1%|
|Non-GAAP gross margin on net product sales||90%||92%|
|Income tax effect of GAAP to non-GAAP reconciling items||1%||1%|
|(a)||This press release uses non-GAAP R&D, non-GAAP SG&A, non-GAAP COGS, non-GAAP gross margin on net product sales, non-GAAP other income (expense), net, non-GAAP ETR, non-GAAP net income, non-GAAP net income per share, total revenues excluding
The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company's control (such as the Company's stock price on the dates share-based grants are issued or changes in the fair value of the Company's investments in equity securities) or items that are not associated with normal, recurring operations (such as restructuring- or integration-related expenses). Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. With respect to free cash flows, the Company believes that this non-GAAP measure provides a further measure of the Company’s operations' ability to generate cash flows. Additionally, such non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company's core business operations. However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.
|(b)||The casirivimab and imdevimab antibody cocktail for COVID-19 is known as
|(c)||The Company's 2023 financial guidance does not assume the completion of any significant business development transactions not completed as of the date of this press release.|
|(d)||Gross margin on net product sales represents gross profit expressed as a percentage of total net product sales recorded by the Company. Gross profit is calculated as net product sales less cost of goods sold.|
|(e)||Corresponding reimbursements from collaborators and others for manufacturing of commercial supplies is recorded within revenues.|
|(f)||Beginning with the first quarter of 2022, the Company added Acquired in-process research and development as a new line item to its Statements of Operations, which includes IPR&D acquired in connection with asset acquisitions as well as up-front/opt-in payments related to license and collaboration agreements. Amounts recorded in this line would have historically been recorded to Research and development expenses. Prior period amounts have been reclassified to conform with the current period's presentation.
Beginning with the first quarter of 2022, IPR&D expenses are no longer excluded in the determination of non-GAAP financial results. Prior period non-GAAP results have also been updated to reflect these changes.
Conference Call Information
Regeneron will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2022 financial and operating results on
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about Regeneron, please visit www.regeneron.com or follow @Regeneron on Twitter.
Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Non-GAAP Financial Measures
This press release and/or the financial results attached to this press release include amounts that are considered "non-GAAP financial measures" under
|Investor Relations||Corporate Communications|
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
|Cash and marketable securities||$||14,334.1||$||12,532.7|
|Accounts receivable, net||5,328.7||6,036.5|
|Property, plant, and equipment, net||3,763.0||3,482.2|
|Intangible assets, net||915.5||6.7|
|Deferred tax assets||1,723.7||876.9|
|Liabilities and stockholders' equity:|
|Accounts payable, accrued expenses, and other liabilities||$||3,301.4||$||3,451.0|
|Finance lease liabilities||720.0||719.7|
|Total liabilities and stockholders' equity||$||29,214.5||$||25,434.8|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In millions, except per share data)
|Three Months Ended
|Net product sales||$||1,699.3||$||3,975.2||$||6,893.7||$||12,117.2|
|Research and development||1,043.1||737.6||3,592.5||2,860.1|
|Acquired in-process research and development||30.0||48.0||255.1||48.0|
|Selling, general, and administrative||660.5||559.6||2,115.9||1,824.9|
|Cost of goods sold||302.2||811.7||800.0||1,773.1|
|Cost of collaboration and contract manufacturing||238.4||170.9||760.4||664.4|
|Other operating (income) expense, net||(6.6||)||(15.8||)||(89.9||)||(45.6||)|
|Income from operations||1,146.8||2,639.7||4,738.9||8,946.8|
|Other income (expense):|
|Other income (expense), net||195.3||(122.2||)||179.3||436.3|
|Income before income taxes||1,324.7||2,503.4||4,858.8||9,325.8|
|Income tax expense||127.6||274.4||520.4||1,250.5|
|Net income per share - basic||$||11.19||$||20.99||$||40.51||$||76.40|
|Net income per share - diluted||$||10.50||$||19.69||$||38.22||$||71.97|
|Weighted average shares outstanding - basic||107.0||106.2||107.1||105.7|
|Weighted average shares outstanding - diluted||114.0||113.2||113.5||112.2|
|* Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. See note (f) above for additional information.|
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited)
(In millions, except per share data)
|Three Months Ended
|R&D: Stock-based compensation expense||131.0||102.9||406.8||316.6|
|R&D: Acquisition-related integration costs||1.4||—||17.0||—|
|SG&A: Stock-based compensation expense||78.4||64.2||256.4||213.3|
|SG&A: Acquisition-related integration costs and other||3.5||—||6.6||5.6|
|COGS: Stock-based compensation expense||22.6||21.3||61.8||71.8|
|COGS: Intangible asset amortization expense||19.7||—||34.8||—|
|COGS: Charges related to
|GAAP other income (expense), net||$||177.9||$||(136.3||)||$||119.9||$||379.0|
|Other income/expense: (Gains) losses on investments||(80.5||)||137.6||36.8||(387.0||)|
|Non-GAAP other income (expense), net||$||97.4||$||1.3||$||156.7||$||(8.0||)|
|GAAP net income||$||1,197.1||$||2,229.0||$||4,338.4||$||8,075.3|
|Total of GAAP to non-GAAP reconciling items above||309.8||557.7||1,016.8||452.0|
|Income tax effect of GAAP to non-GAAP reconciling items||(57.9||)||(110.0||)||(191.3||)||(73.7||)|
|Non-GAAP net income||$||1,449.0||$||2,676.7||$||5,163.9||$||8,453.6|
|Non-GAAP net income per share - basic||$||13.54||$||25.20||$||48.22||$||79.98|
|Non-GAAP net income per share - diluted||$||12.56||$||23.42||$||44.98||$||74.35|
|Shares used in calculating:|
|Non-GAAP net income per share - basic||107.0||106.2||107.1||105.7|
|Non-GAAP net income per share - diluted||115.4||114.3||114.8||113.7|
|* Prior period results have been revised to reflect certain changes to amounts excluded from non-GAAP results. See note (f) above for additional information.|
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited) (continued)
|Three Months Ended
|Global gross profit payment from Roche in connection with sales of Ronapreve||396.4||—||627.3||361.8|
|Total revenues excluding
|Effective tax rate reconciliation:|
|Income tax effect of GAAP to non-GAAP reconciling items||1.7%||1.6%||1.4%||0.1%|
|Free cash flow reconciliation:|
|Net cash provided by operating activities||$||5,014.9||$||7,081.3|
|Free cash flow||$||4,424.8||$||6,529.4|
COLLABORATION REVENUE (Unaudited)
|Three Months Ended
|Sanofi collaboration revenue:|
|Regeneron's share of profits in connection with commercialization of antibodies||$||619.0||$||387.8||$||2,082.0||$||1,363.0|
|Sales-based milestones earned||50.0||—||100.0||50.0|
|Reimbursement for manufacturing of commercial supplies||166.9||127.6||633.7||488.8|
|Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside
|Reimbursement for manufacturing of ex-
|Total Sanofi collaboration revenue||835.9||517.9||2,855.7||1,902.2|
|Bayer collaboration revenue:|
|Regeneron's share of profits in connection with commercialization of EYLEA outside
|Reimbursement for manufacturing of ex-
|One-time payment in connection with change in
|Total Bayer collaboration revenue||355.1||372.4||1,430.7||1,409.3|
|Other collaboration revenue:|
|Global gross profit payment from Roche in connection with sales of
|Total collaboration revenue||$||1,587.4||$||890.3||$||4,914.1||$||3,673.3|
NET PRODUCT SALES OF REGENERON-DISCOVERED PRODUCTS (Unaudited)
|Three Months Ended
|(a) Regeneron records net product sales of EYLEA in
|(b) Sanofi records global net product sales of Dupixent and Kevzara. The Company records its share of profits/losses in connection with global sales of Dupixent and Kevzara.|
|(c) Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in
|(d) Regeneron records net product sales of Praluent in
|(e) Regeneron records net product sales of
|(f) Included in this line item are products which are sold by the Company and others. Refer to "Fourth Quarter 2022 Financial Results" section above for a complete listing of net product sales recorded by the Company. Not included in this line item are net product sales of ARCALYST subsequent to the first quarter of 2021, which are recorded by Kiniksa.|
Source: Regeneron Pharmaceuticals, Inc.